Literature DB >> 20123549

Rodent models of treatment-induced motor complications in Parkinson's disease.

M Angela Cenci1, K Elisabet Ohlin.   

Abstract

Treatment-induced motor complications represent a major clinical problem in Parkinson's disease (PD). Pharmacological dopamine (DA) replacement with l-dopa causes motor fluctuations and abnormal involuntary movements (dyskinesia) in the vast majority of the patients. Intrastriatal grafts of embryonic dopaminergic neurons can cause dyskinesia too, as shown by clinical trials of neural transplantation in PD. Animals models of these complications can be produced in rats and mice in which the nigrostriatal DA pathway has been severely damaged. Rodent models allow investigators to explore mechanistic hypotheses at the cellular and molecular level. Moreover, the rat model of L-dopa-induced abnormal involuntary movements shows both face validity and predictive validity relative to the corresponding disorder in primates, and provides a cost effective tool to evaluate novel antidyskinetic interventions. This article reviews the strategies that have been used to reproduce different motor complications of PD treatment in rodents, and comments on their range of applicability. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20123549     DOI: 10.1016/S1353-8020(09)70828-4

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

Review 1.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

2.  Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.

Authors:  Elaine Del-Bel; Fernando Eduardo Padovan-Neto; Raphael Escorsim Szawka; Célia Aparecida da-Silva; Rita Raisman-Vozari; Janete Anselmo-Franci; Angélica Caroline Romano-Dutra; Francisco Silveira Guimaraes
Journal:  Neurotox Res       Date:  2013-06-27       Impact factor: 3.911

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian Striatum.

Authors:  Kathy Steece-Collier; David J Rademacher; Katherine Soderstrom
Journal:  Basal Ganglia       Date:  2012-02-11

Review 5.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

6.  Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Christine Konradi
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 7.  Nicotine as a potential neuroprotective agent for Parkinson's disease.

Authors:  Maryka Quik; Xiomara A Perez; Tanuja Bordia
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

8.  Orthodontic treatment-induced temporal alteration of jaw-opening reflex excitability.

Authors:  Au Sasaki; Naoya Hasegawa; Kazunori Adachi; Hiroshi Sakagami; Naoto Suda
Journal:  J Neurophysiol       Date:  2017-07-19       Impact factor: 2.714

9.  Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Parkinsons Dis       Date:  2011-10-11

Review 10.  The Rodent Models of Dyskinesia and Their Behavioral Assessment.

Authors:  Qiwei Peng; Shaoping Zhong; Yang Tan; WeiQi Zeng; Ji Wang; Chi Cheng; Xiaoman Yang; Yi Wu; Xuebing Cao; Yan Xu
Journal:  Front Neurol       Date:  2019-10-11       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.